Advertisement

Biomarkers

  • Maria Dorobantu
  • Miruna Mihaela Micheu
Chapter
Part of the Updates in Hypertension and Cardiovascular Protection book series (UHCP)

Abstract

Even though heart failure (HF) is a global public health problem, its diagnosis is often quite challenging, especially in the initial stages. Biomarkers are useful instruments which could facilitate the early diagnosis and prompt therapy initiation in a patient-tailored manner. Substantial advancements have been made in recent years, so reasonably priced omics-based technologies have permitted on the dot identification of a wide array of biomarkers. But not all biomarkers can be used in clinics as these must be precise, sensitive, and specific for the pathology investigated. HF is characterized by a systemic inflammatory response, myocardial fibrosis, and increased myocyte stress leading to organ damage. In view of that, these biomarkers are categorized into markers related to fibrosis, inflammation, myocyte stress, and microRNAs. The validation of biomarkers is hindered by low statistical power and poor reproducibility of results. So, the quest to ascertain high-quality biomarkers having high accuracy and robustness has not yet come to an end, and further research in this field is needed.

Keywords

Hypertension Heart failure Biomarkers Inflammation Fibrosis Myocyte stress 

Notes

Acknowledgement

Funding: This work was supported by a grant of the Romanian National Authority for Scientific Research and Innovation, CNCS/CCCDI—UEFISCDI, project number PN-III-P2-2.1-PED-2016-1333, within PNCDI III.

References

  1. 1.
    Ueland T, Gullestad L, Nymo SH, et al. Inflammatory cytokines as biomarkers in heart failure. Clin Chim Acta. 2015;443:71–7.  https://doi.org/10.1016/j.cca.2014.09.001.CrossRefPubMedGoogle Scholar
  2. 2.
    Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBr PE, BLW. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128:e240–327.  https://doi.org/10.1161/cir.0b013e31829e8776.CrossRefPubMedGoogle Scholar
  3. 3.
    Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136:e137–61.  https://doi.org/10.1161/CIR.0000000000000509.CrossRefPubMedGoogle Scholar
  4. 4.
    Shah RV, Chen-Tournoux AA, Picard MH, et al. Serum levels of the interleukin-1 receptor family member ST2, cardiac structure and function, and long-term mortality in patients with acute dyspnea. Circ Heart Fail. 2009;2:311–9.  https://doi.org/10.1161/CIRCHEARTFAILURE.108.833707.CrossRefPubMedGoogle Scholar
  5. 5.
    Bayes-Genis A, Zhang Y, Ky B. ST2 and patient prognosis in chronic heart failure. Am J Cardiol. 2015;115:64B–9B.  https://doi.org/10.1016/j.amjcard.2015.01.043.CrossRefPubMedGoogle Scholar
  6. 6.
    Wang Y-C, Yu C-C, Chiu F-C, et al. Soluble ST2 as a biomarker for detecting stable heart failure with a normal ejection fraction in hypertensive patients. J Card Fail. 2013;19:163–8.  https://doi.org/10.1016/j.cardfail.2013.01.010.CrossRefPubMedGoogle Scholar
  7. 7.
    Bartunek J, Delrue L, Van Durme F, et al. Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load. J Am Coll Cardiol. 2008;52:2166–74.  https://doi.org/10.1016/j.jacc.2008.09.027.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Carrasco-Sánchez FJ, Aramburu-Bodas O, Salamanca-Bautista P, et al. Predictive value of serum galectin-3 levels in patients with acute heart failure with preserved ejection fraction. Int J Cardiol. 2013;169:177–82.  https://doi.org/10.1016/j.ijcard.2013.08.081.CrossRefPubMedGoogle Scholar
  9. 9.
    Zile MR, Baicu CF, Ikonomidis J, et al. Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. Circulation. 2015;131:1247–59.  https://doi.org/10.1161/CIRCULATIONAHA.114.013215.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Kim H, Lee J, Hyun JW, Park JW, Joo HG, Shin T. Expression and immunohistochemical localization of galectin-3 in various mouse tissues. Cell Biol Int. 2007;31:655–62.  https://doi.org/10.1016/J.CELLBI.2006.11.036.CrossRefPubMedGoogle Scholar
  11. 11.
    Yao Y, Shen D, Chen R, et al. Galectin-3 predicts left ventricular remodeling of hypertension. J Clin Hypertens. 2016;18:506–11.  https://doi.org/10.1111/jch.12757.CrossRefGoogle Scholar
  12. 12.
    de Boer RA, Voors AA, Muntendam P, et al. Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail. 2009;11:811–7.  https://doi.org/10.1093/eurjhf/hfp097.CrossRefPubMedGoogle Scholar
  13. 13.
    Sharma UC, Pokharel S, van Brakel TJ, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 2004;110:3121–8.  https://doi.org/10.1161/01.CIR.0000147181.65298.4D.CrossRefPubMedGoogle Scholar
  14. 14.
    de Boer RA, Lok DJA, Jaarsma T, et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med. 2011;43:60–8.  https://doi.org/10.3109/07853890.2010.538080.CrossRefPubMedGoogle Scholar
  15. 15.
    Ho JE, Liu C, Lyass A, et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol. 2012;60:1249–56.  https://doi.org/10.1016/j.jacc.2012.04.053.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    van Kimmenade RR, Januzzi JLJ, Ellinor PT, et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol. 2006;48:1217–24.  https://doi.org/10.1016/j.jacc.2006.03.061.CrossRefPubMedGoogle Scholar
  17. 17.
    Martos R, Baugh J, Ledwidge M, et al. Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation. 2007;115:888–95.  https://doi.org/10.1161/CIRCULATIONAHA.106.638569.CrossRefPubMedGoogle Scholar
  18. 18.
    Bielecka-Dabrowa A, Michalska-Kasiczak M, Gluba A, et al. Biomarkers and echocardiographic predictors of myocardial dysfunction in patients with hypertension. Sci Rep. 2015;5:8916.  https://doi.org/10.1038/srep08916.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Demir M, Acartürk E, Inal T, et al. Procollagen type I carboxy-terminal peptide shows left ventricular hypertrophy and diastolic dysfunction in hypertensive patients. Cardiovasc Pathol. 2007;16:69–74.  https://doi.org/10.1016/j.carpath.2006.09.010.CrossRefPubMedGoogle Scholar
  20. 20.
    Plaksej R, Kosmala W, Frantz S, et al. Relation of circulating markers of fibrosis and progression of left and right ventricular dysfunction in hypertensive patients with heart failure. J Hypertens. 2009;27:2483–91.  https://doi.org/10.1097/HJH.0b013e3283316c4d.CrossRefPubMedGoogle Scholar
  21. 21.
    Tang WH, Shrestha K, Troughton RW, et al. Integrating plasma high-sensitivity C-reactive protein and myeloperoxidase for risk prediction in chronic systolic heart failure. Congest Heart Fail. 2011;17:105–9.  https://doi.org/10.1111/j.1751-7133.2011.00221.x.CrossRefPubMedGoogle Scholar
  22. 22.
    Querejeta R, López B, González A, et al. Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis. Circulation. 2004;110:1263–8.  https://doi.org/10.1161/01.CIR.0000140973.60992.9A.CrossRefPubMedGoogle Scholar
  23. 23.
    Stakos DA, Tziakas DN, Chalikias GK, et al. Associations between collagen synthesis and degradation and aortic function in arterial hypertension. Am J Hypertens. 2010;23:488–94.  https://doi.org/10.1038/ajh.2010.2.CrossRefPubMedGoogle Scholar
  24. 24.
    Piotrowski G, Banach M, Gerdts E, et al. Left atrial size in hypertension and stroke. J Hypertens. 2011;29:1988–93.  https://doi.org/10.1097/HJH.0b013e32834a98db.CrossRefPubMedGoogle Scholar
  25. 25.
    González A, López B, Querejeta R, et al. Filling pressures and collagen metabolism in hypertensive patients with heart failure and normal ejection fraction. Hypertension. 2010;55:1418–24.  https://doi.org/10.1161/HYPERTENSIONAHA.109.149112.CrossRefPubMedGoogle Scholar
  26. 26.
    Kuwahara F, Kai H, Tokuda K, et al. Hypertensive myocardial fibrosis and diastolic dysfunction: another model of inflammation? Hypertension. 2004;43:739–45.  https://doi.org/10.1161/01.HYP.0000118584.33350.7d.CrossRefPubMedGoogle Scholar
  27. 27.
    Zile MR, DeSantis SM, Baicu CF, et al. Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure. Circ Heart Fail. 2011;4:246–56.  https://doi.org/10.1161/CIRCHEARTFAILURE.110.958199.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Tromp J, van der Pol A, Klip IT, et al. Fibrosis marker syndecan-1 and outcome in patients with heart failure with reduced and preserved ejection fraction. Circ Heart Fail. 2014;7:457–62.  https://doi.org/10.1161/CIRCHEARTFAILURE.113.000846.CrossRefPubMedGoogle Scholar
  29. 29.
    Reitsma S, Slaaf DW, Vink H, et al. The endothelial glycocalyx: composition, functions, and visualization. Pflugers Arch. 2007;454:345–59.CrossRefGoogle Scholar
  30. 30.
    Kim YH, Nijst P, Kiefer K, Tang WHW. Endothelial glycocalyx as biomarker for cardiovascular diseases: mechanistic and clinical implications. Curr Heart Fail Rep. 2017;14:117–26.CrossRefGoogle Scholar
  31. 31.
    Johar D, Bernstein L. A targeted approach toward more accurate assessment of hypertension. Egypt J Chest Dis Tuberc. 2017;66:517–36.  https://doi.org/10.1016/j.ejcdt.2017.01.002.CrossRefGoogle Scholar
  32. 32.
    Frangogiannis NG. Syndecan-1: a critical mediator in cardiac fibrosis. Hypertension. 2010;55:233–5.CrossRefGoogle Scholar
  33. 33.
    Okuyan E, Uslu A, Çakar MA, et al. Homocysteine levels in patients with heart failure with preserved ejection fraction. Cardiology. 2010;117:21–7.  https://doi.org/10.1159/000320106.CrossRefPubMedGoogle Scholar
  34. 34.
    Song TT, Cui R, Guo QH, Jia HD, Liu L. The correlation and its significance of BNP, homocysteine and C-reactive protein level in elderly heart failure patients with preserved ventricular ejection fraction and hypertension. Labeled Immunoassays Clin Med. 2016;24:200–3.  https://doi.org/10.11748/BJMY.ISSN.1006-1703.2017.02.019.
  35. 35.
    Joseph J, Washington A, Joseph L, et al. Hyperhomocysteinemia leads to adverse cardiac remodeling in hypertensive rats. Am J Physiol Heart Circ Physiol. 2002;283:H2567–74.  https://doi.org/10.1152/ajpheart.00475.2002.CrossRefPubMedGoogle Scholar
  36. 36.
    Joseph J, Loscalzo J. Methoxistasis: integrating the roles of homocysteine and folic acid in cardiovascular pathobiology. Nutrients. 2013;5:3235–56.  https://doi.org/10.3390/nu5083235.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Gibelin P, Serre S, Candito M, et al. Prognostic value of homocysteinemia in patients with congestive heart failure. Clin Chem Lab Med. 2006;44:813–6.CrossRefGoogle Scholar
  38. 38.
    Takeishi Y, Niizeki T, Arimoto T, et al. Serum resistin is associated with high risk in patients with congestive heart failure—a novel link between metabolic signals and heart failure. Circ J. 2007;71:460–4.  https://doi.org/10.1253/circj.71.460.CrossRefPubMedGoogle Scholar
  39. 39.
    Papadopoulos DP, Perrea D, Thomopoulos C, et al. Masked hypertension and atherogenesis: the impact on adiponectin and resistin plasma levels. J Clin Hypertens. 2009;11:61–5.  https://doi.org/10.1111/j.1751-7176.2008.00070.x.CrossRefGoogle Scholar
  40. 40.
    Ravassa S, Beloqui O, Varo N, et al. Association of cardiotrophin-1 with left ventricular systolic properties in asymptomatic hypertensive patients. J Hypertens. 2013;31:1.  https://doi.org/10.1097/HJH.0b013e32835ca903.CrossRefGoogle Scholar
  41. 41.
    Song K, Wang S, Huang B, et al. Plasma cardiotrophin-1 levels are associated with hypertensive heart disease: a meta-analysis. J Clin Hypertens. 2014;16:686–92.  https://doi.org/10.1111/jch.12376.CrossRefGoogle Scholar
  42. 42.
    Cesari M, Penninx BWJH, Newman AB, et al. Inflammatory markers and onset of cardiovascular events: results from the health ABC study. Circulation. 2003;108:2317–22.  https://doi.org/10.1161/01.CIR.0000097109.90783.FC.CrossRefPubMedGoogle Scholar
  43. 43.
    Matsumoto M, Tsujino T, Lee-Kawabata M, et al. Serum interleukin-6 and C-reactive protein are markedly elevated in acute decompensated heart failure patients with left ventricular systolic dysfunction. Cytokine. 2010;49:264–8.  https://doi.org/10.1016/j.cyto.2009.11.006.CrossRefPubMedGoogle Scholar
  44. 44.
    Navarro-González JF, Mora C, Muros M, et al. Association of tumor necrosis factor-alpha with early target organ damage in newly diagnosed patients with essential hypertension. J Hypertens. 2008;26:2168–75.  https://doi.org/10.1097/HJH.0b013e32830e2545.CrossRefPubMedGoogle Scholar
  45. 45.
    Dunlay SM, Weston SA, Redfield MM, et al. Tumor necrosis factor-alpha and mortality in heart failure: a community study. Circulation. 2008;118:625–31.  https://doi.org/10.1161/CIRCULATIONAHA.107.759191.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Luft FC. Angiotensin, inflammation, hypertension, and cardiovascular disease. Curr Hypertens Rep. 2001;3:61–7.CrossRefGoogle Scholar
  47. 47.
    Collier P, Watson CJ, Voon V, et al. Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure? Eur J Heart Fail. 2011;13:1087–95.  https://doi.org/10.1093/eurjhf/hfr079.CrossRefPubMedGoogle Scholar
  48. 48.
    Trojnarska O, Gwizdała A, Katarzyński S, et al. Evaluation of exercise capacity with cardiopulmonary exercise testing and BNP levels in adult patients with single or systemic right ventricles. Arch Med Sci. 2010;6:192–7.  https://doi.org/10.5114/aoms.2010.13893.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Xue H, Fu Z, Chen Y, et al. The association of growth differentiation factor-15 with left ventricular hypertrophy in hypertensive patients. PLoS One. 2012;7:e46534.  https://doi.org/10.1371/journal.pone.0046534.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Kouris NT, Zacharos ID, Kontogianni DD, et al. The significance of CA125 levels in patients with chronic congestive heart failure. Correlation with clinical and echocardiographic parameters. Eur J Heart Fail. 2005;7:199–203.  https://doi.org/10.1016/j.ejheart.2004.07.015.CrossRefPubMedGoogle Scholar
  51. 51.
    Hung C-L, Hung T-C, Liu C-C, et al. Relation of carbohydrate antigen-125 to left atrial remodeling and its prognostic usefulness in patients with heart failure and preserved left ventricular ejection fraction in women. Am J Cardiol. 2012;110:993–1000.  https://doi.org/10.1016/j.amjcard.2012.05.030.CrossRefPubMedGoogle Scholar
  52. 52.
    Martos R, Baugh J, Ledwidge M, et al. Diagnosis of heart failure with preserved ejection fraction: improved accuracy with the use of markers of collagen turnover. Eur J Heart Fail. 2009;11:191–7.  https://doi.org/10.1093/eurjhf/hfn036.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Sawada Y, Suda M, Yokoyama H, et al. Stretch-induced hypertrophic growth of cardiocytes and processing of brain-type natriuretic peptide are controlled by proprotein-processing endoprotease furin. J Biol Chem. 1997;272:20545–54.  https://doi.org/10.1074/jbc.272.33.20545.CrossRefPubMedGoogle Scholar
  54. 54.
    Yan W, Wu F, Morser J, Wu Q. Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide-converting enzyme. Proc Natl Acad Sci U S A. 2000;97:8525–9.  https://doi.org/10.1073/pnas.150149097.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Mottram PM, Leano R, Marwick TH. Usefulness of B-type natriuretic peptide in hypertensive patients with exertional dyspnea and normal left ventricular ejection fraction and correlation with new echocardiographic indexes of systolic and diastolic function. Am J Cardiol. 2003;92:1434–8.CrossRefGoogle Scholar
  56. 56.
    Tschöpe C, Kašner M, Westermann D, et al. The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements. Eur Heart J. 2005;26:2277–84.  https://doi.org/10.1093/eurheartj/ehi406.CrossRefPubMedGoogle Scholar
  57. 57.
    Gluba A, Bielecka A, Mikhailidis DP, et al. An update on biomarkers of heart failure in hypertensive patients. J Hypertens. 2012;30:1681–9.  https://doi.org/10.1097/HJH.0b013e3283569a9c.CrossRefPubMedGoogle Scholar
  58. 58.
    Almeida P, Azevedo A, Rodrigues R, et al. B-type natriuretic peptide and left ventricular hypertrophy in hypertensive patients. Rev Port Cardiol. 2003;22:327–36.PubMedGoogle Scholar
  59. 59.
    Nishikimi T, Morimoto A, Ishikawa K, et al. Different secretion patterns of adrenomedullin, brain natriuretic peptide, and atrial natriuretic peptide during exercise in hypertensive and normotensive subjects. Clin Exp Hypertens. 1997;19:503–18.CrossRefGoogle Scholar
  60. 60.
    Ishimitsu T, Nishikimi T, Saito Y, et al. Plasma levels of adrenomedullin, a newly identified hypotensive peptide, in patients with hypertension and renal failure. J Clin Invest. 1994;94:2158–61.  https://doi.org/10.1172/JCI117573.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Pousset F, Masson F, Chavirovskaia O, et al. Plasma adrenomedullin, a new independent predictor of prognosis in patients with chronic heart failure. Eur Heart J. 2000;21:1009–14.  https://doi.org/10.1053/euhj.1999.1904.CrossRefPubMedGoogle Scholar
  62. 62.
    Yu CM, Cheung BM, Leung R, et al. Increase in plasma adrenomedullin in patients with heart failure characterised by diastolic dysfunction. Heart. 2001;86:155–60.CrossRefGoogle Scholar
  63. 63.
    Xue Y, Taub P, Iqbal N, et al. Elevated mid-region pro-adrenomedullin is associated with increased mortality in stable outpatients with diastolic dysfunction. J Card Fail. 2011;17:S3.  https://doi.org/10.1016/j.cardfail.2011.06.010.CrossRefGoogle Scholar
  64. 64.
    Gottsäter M, Ford LB, Östling G, et al. Adrenomedullin is a marker of carotid plaques and intima–media thickness as well as brachial pulse pressure. J Hypertens. 2013;31:1959–65.  https://doi.org/10.1097/HJH.0b013e328362fe99.CrossRefPubMedGoogle Scholar
  65. 65.
    Ertmer C, Van Aken H, Westphal M. Adrenomedullin in the treatment of cardiovascular dysfunction and sepsis. In: Intensive care medicine.Yearbook of Intensive Care and Emergency Medicine. Springer: Berlin, Heidelberg. 2007;2007:81–95.Google Scholar
  66. 66.
    Watson CJ, Gupta SK, O’Connell E, et al. MicroRNA signatures differentiate preserved from reduced ejection fraction heart failure. Eur J Heart Fail. 2015;17:405–15.  https://doi.org/10.1002/ejhf.244.CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Dong S, Ma W, Hao B, et al. microRNA-21 promotes cardiac fibrosis and development of heart failure with preserved left ventricular ejection fraction by up-regulating Bcl-2. Int J Clin Exp Pathol. 2014;7(2):565–74.PubMedPubMedCentralGoogle Scholar
  68. 68.
    Marketou M, Kontaraki J, Parthenakis F, et al. MicroRNA-21 and microRNA-133 levels in peripheral blood mononuclear cells are associated with functional capacity in patients with heart failure with preserved ejection fraction. Eur Heart J. 2016;37:723–4.  https://doi.org/10.1093/eurheartj/ehw433.CrossRefGoogle Scholar
  69. 69.
    Manzano-Fernndez S, Mueller T, Pascual-Figal D, et al. Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. Am J Cardiol. 2011;107:259–67.  https://doi.org/10.1016/j.amjcard.2010.09.011.CrossRefGoogle Scholar
  70. 70.
    Bošnjak I, Selthofer-Relatić K, Včev A. Prognostic value of galectin-3 in patients with heart failure. Dis Markers. 2015;2015:690205.  https://doi.org/10.1155/2015/690205.CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    Krum H, Elsik M, Schneider HG, et al. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy. Circ Heart Fail. 2011;4:561–8.  https://doi.org/10.1161/CIRCHEARTFAILURE.110.960716.CrossRefPubMedGoogle Scholar
  72. 72.
    Ahmed SH, Clark LL, Pennington WR, et al. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation. 2006;113:2089–96.  https://doi.org/10.1161/CIRCULATIONAHA.105.573865.CrossRefPubMedGoogle Scholar
  73. 73.
    Maisel A, Barnard D, Jaski B, et al. Primary results of the HABIT trial (heart failure assessment with BNP in the home). J Am Coll Cardiol. 2013;61:1726–35.  https://doi.org/10.1016/j.jacc.2013.01.052.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Maria Dorobantu
    • 1
    • 2
  • Miruna Mihaela Micheu
    • 1
  1. 1.Clinical Emergency Hospital of BucharestBucharestRomania
  2. 2.Cardiology Department‘Carol Davila’ University of Medicine and Pharmacy in BucharestBucharestRomania

Personalised recommendations